Medical AI company Lunit announced on the 15th that it will participate in the American Association for Cancer Research Annual Meeting (AACR 2023) held in Orlando, Florida, USA from the 14th to the 19th of next month (local time), presenting five research abstracts applying AI biomarkers and AI pathology analysis solutions to various cancer types.
AACR is a globally prestigious cancer society with 50,000 members from 120 countries worldwide. It is considered one of the world's top three cancer societies along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). Every year at AACR, medical professionals and pharmaceutical biotech companies from around the world gather to share the latest research achievements, and Lunit has participated in AACR for five consecutive years since 2019, presenting the latest research results related to AI-based biomarkers.
At this conference, Lunit will present various research results using the AI biomarker platform 'Lunit SCOPE,' including ▲performance validation of a non-small cell lung cancer KRAS G12C mutation prediction model ▲performance evaluation of an AI-based universal immunohistochemistry analyzer ▲performance validation of Lunit SCOPE IO in predicting immune checkpoint inhibitor treatment efficacy in advanced and metastatic cholangiocarcinoma ▲quantitative analysis of tumor-infiltrating lymphocytes at the tumor-stroma interface in various cancer types ▲and immunophenotype analysis results of Lunit SCOPE in ovarian epithelial cancer.
Seobum Seok, CEO of Lunit, said, "At this AACR conference, we will present research results using Lunit SCOPE on various cancer types that we have not previously addressed," adding, "We will continue to devote efforts to related academic research and product development to provide the most suitable treatment methods for cancer patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
